false
0001633932
A1
0001633932
2024-08-05
2024-08-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________
FORM 8-K
___________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): August
5, 2024
___________
ESSA Pharma Inc.
(Exact name of registrant as specified in its charter)
___________
British Columbia, Canada
(State or other jurisdiction of incorporation) |
001-37410
(Commission File Number) |
98-1250703
(IRS Employer Identification No.) |
|
|
|
Suite 720, 999 West Broadway, Vancouver, British
Columbia, Canada
(Address of principal executive offices) |
V5Z 1K5
(Zip Code) |
Registrant’s telephone number, including area
code: (778) 331-0962
_____________________
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of
each class |
Trading
Symbol(s) |
Name of
each exchange on which registered |
Common Shares, no par value |
EPIX |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
The following information is filed pursuant to Item
2.02, “Results of Operations and Financial Condition.”
On August 5, 2024, ESSA Pharma Inc. (the “Company”)
issued a press release announcing its financial results for the fiscal quarter ended June 30, 2024. A copy of the press release is attached
as Exhibit 99.1 to this Form 8-K.
The information provided under this Item (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
|
|
|
(d) Exhibits |
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
_____ ESSA PHARMA INC. ___
(Registrant) |
Date: August 5, 2024 |
|
|
|
By: |
/s/ David Wood |
|
|
Name: David Wood
Title: Chief Financial Officer |
Exhibit 99.1
ESSA Pharma Provides
Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2024
On track to report
updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens
in the second half of 2024
Presentation of Phase
1b monotherapy results expected to be reported in the second half of 2024
Phase 2 dose expansion
underway evaluating masofaniten plus enzalutamide in patients with mCRPC naïve to second generation antiandrogens; ESSA projecting
completion of enrollment in the first quarter of 2025, with preliminary data expected in mid-2025
Cash runway sufficient
to fund operations well beyond 2025
SOUTH SAN FRANCISCO, California and VANCOUVER,
Canada, August 5, 2024 - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical
company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial
results for the fiscal third quarter ended June 30, 2024.
“With continued focus on execution,
we are progressing towards a stream of significant milestones throughout the next nine to twelve months, with the first being the presentation
at ESMO of more mature durability data from the Phase 1 dose escalation study evaluating masofaniten combined with enzalutamide in patients
with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens,” said David Parkinson, MD, President
and CEO of ESSA. “We are focused on the enrollment of the Phase 2 dose expansion study evaluating masofaniten in combination with
enzalutamide, with 25 sites activated in the US, Canada and Australia and an additional 14 sites being activated in Europe. We look forward
to reporting key data across these trials throughout the remainder of this year through 2025.”
Third Quarter Fiscal 2024 and Recent Highlights
Masofaniten Combination Studies
| • | Phase 1/2 study is still ongoing evaluating masofaniten in combination
with enzalutamide in patients with metastatic castration-resistant prostate cancer (“mCRPC”) naïve to second-generation
antiandrogens but may have been treated with chemotherapy in the metastatic castration-sensitive setting. The latest reported results,
which were presented at the ASCO-GU symposium in January 2024, demonstrated that the combination regimen continues to be well tolerated
at the dose levels tested in up to 25 cycles of dosing in some patients. Reductions in PSA were observed across evaluable patients for
efficacy in all dosing cohorts (n=16). Across all dosing cohorts, 88% of patients achieved PSA50, 81% of patients achieved PSA90, 69%
of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA <0.2ng/mL. While the data for time to PSA progression
were still maturing, the median time to PSA progression was reported as 16.6 months with a median follow up at that time of 11.1 months.
ESSA plans to report updated data from the Phase 1 dose escalation study at the European Society for Medical Oncology (ESMO) 2024 congress.
.. |
| • | Masofaniten continues to be evaluated in combination with enzalutamide compared
to enzalutamide monotherapy in a Phase 2 dose randomized study in patients with mCRPC naïve to second-generation antiandrogens but
who may have been treated with chemotherapy in the metastatic castration-sensitive setting. Enrollment in the Phase 2 portion of this
Phase 1/2 study is expected to be completed during the first quarter of 2025. The study is currently enrolling at approximately 25 sites
in the US., Canada, and Australia. Expansion to European clinical sites is in progress with an additional 14 clinical sites planned to
be activated by the third quarter of 2024. ESSA is on track to report preliminary data from the Phase 2 dose expansion portion of the
study in mid-2025. |
| • | Two additional masofaniten combination arms are continuing enrollment as part
of the ongoing Phase 1 masofaniten study. One arm is evaluating masofaniten in combination with abiraterone acetate and prednisone in
patients with either metastatic castration-sensitive prostate cancer or mCRPC, while the second arm is evaluating masofaniten in combination
with apalutamide in patients with non-metastatic castration-resistant prostate cancer after 12 weeks of masofaniten single agent. |
| • | Two additional investigator-sponsored studies testing combinations of masofaniten
with darolutamide or enzalutamide in different patient populations are currently enrolling: a) an Australian investigator-sponsored neoadjuvant
study evaluating neoadjuvant use of the combination of masofaniten and darolutamide compared to darolutamide monotherapy in high-risk
patients undergoing prostatectomy and b) an investigator-sponsored study which is testing masofaniten and enzalutamide in metastatic castration-sensitive
prostate cancer patients. |
Masofaniten Monotherapy Study
| • | ESSA remains on track to complete the Phase 1b masofaniten monotherapy
study evaluating masofaniten in patients with mCRPC resistant to second-generation antiandrogens. The initial results from the monotherapy
study were reported at the 2023 ASCO-GU Symposium, and demonstrated that masofaniten monotherapy was well-tolerated, achieved clinically
significant exposures, and showed preliminary signals of anti-tumor activity in a subset of patients. ESSA plans to present the complete
Phase 1b monotherapy results in the second half of 2024 at a medical conference. |
Summary Financial results
(Amounts expressed in U.S. dollars)
| • | Net Loss. ESSA recorded a net loss of $7.2 million for the third quarter
ended June 30, 2024, compared to $7.3 million for the third quarter ended June 30, 2023. |
| • | Research and Development ("R&D") expenditures. R&D
expenditures for the third quarter ended June 30, 2024, were $5.5 million compared to $6.3 million for the third quarter ended June 30,
2023, and include non-cash costs related to share-based payments of $851,971 for the third quarter ended 2024 compared to $599,621 for
the third quarter ended 2023. The decrease is largely attributable to reductions in preclinical work with the focus on ongoing clinical
trials. |
| • | General and Administration ("G&A") expenditures. G&A
expenditures for the third quarter ended June 30, 2024, were $3.2 million compared to $2.6 million for the third quarter ended June 30,
2023, and include non-cash costs related to share-based payments of $1,748,227 for the third quarter ended 2024 compared to $561,452 for
the third quarter ended 2023. The net decrease (net of share-based payments) relates to the timing of corporate projects and lower insurance
premiums for the current period. |
Liquidity and Outstanding Share Capital
| • | As of June 30, 2024, the Company had available cash reserves and short-term
investments of $130.7 million. The Company's cash position is expected to be sufficient to fund current and planned operations beyond
2025. |
| • | As of June 30, 2024, the Company had 44,368,959 common shares issued and outstanding. |
| • | In addition, as of June 30, 2024, there were 2,920,000 common shares issuable
upon the exercise of prefunded warrants at an exercise price of $0.0001. |
About ESSA Pharma Inc.
ESSA is a clinical-stage pharmaceutical company
focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please
visit www.essapharma.com, and follow us on X and LinkedIn.
Forward-Looking Statement Disclaimer
This release contains certain information
which, as presented, constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform
Act of 1995 and, and “forward-looking information” within the meaning of Canadian securities laws (collectively, “forward-looking
statements”). Forward-looking statements include, but are not limited to, statements that relate to future events and often addresses
expected future business and financial performance, containing words such as "anticipate", "believe", "plan",
"estimate", "expect", and "intend", statements that an action or event "may", "might",
"could", "should", or "will" be taken or occur, or other similar expressions and includes, but is not limited
to, statements regarding the Company’s plans to report updated data from its studies, the Company’s advancement and evaluation
of masofaniten, the timing of the Company’s studies, enrollment in the Company’s studies, the presentation of Phase 1a and
1b monotherapy results and the Company’s expected cash runway.
Forward-looking statements are subject to
various known and unknown risks and uncertainties, many of which are beyond the ability of ESSA to control or predict, and which may cause
ESSA's actual results, performance or achievements to be materially different from those expressed or implied thereby. Such statements
reflect ESSA's current views with respect to future events, are subject to risks and uncertainties and are necessarily based upon a number
of estimates and assumptions that, while considered reasonable by ESSA as of the date of such statements, are inherently subject to significant
medical, scientific, business, economic, competitive, political and social uncertainties and contingencies. In making forward-looking
statements, ESSA may make various material assumptions, including but not limited to (i) the accuracy of ESSA's financial projections;
(ii) obtaining positive results of clinical trials; (iii) obtaining necessary regulatory approvals; and (iv) general business,
market and economic conditions.
Forward-looking statements are developed based
on assumptions about such risks, uncertainties and other factors set out herein and in ESSA's Annual Report on Form 10-K dated December 12,
2023, under the heading "Risk Factors", a copy of which is available on ESSA's profile on EDGAR at www.sec.gov and on SEDAR+
at www.sedarplus.ca, and as otherwise disclosed from time to time on ESSA's EDGAR and SEDAR+ profiles. Forward-looking statements are
made based on management's beliefs, estimates and opinions on the date that statements are made and ESSA undertakes no obligation to update
forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as may be required by
applicable United States and Canadian securities laws. Readers are cautioned against attributing undue certainty to forward-looking statements.
Contacts
ESSA Pharma, Inc.
David Wood, Chief Financial Officer
778.331.0962
dwood@essapharma.com
Investors and Media:
Argot Partners
212.600.1902
essa@argotpartners.com
ESSA PHARMA INC.
CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS
(Unaudited)
Amounts in thousands of United States dollars
| |
June 30, 2024 | |
September 30, 2023 |
| |
| |
|
Cash | |
$ | 85,985 | | |
$ | 33,702 | |
Prepaids and other assets | |
| 46,681 | | |
| 115,420 | |
| |
| | | |
| | |
Total assets | |
$ | 132,666 | | |
$ | 149,122 | |
| |
| | | |
| | |
Current liabilities | |
| 3,575 | | |
| 3,495 | |
Long-term debt | |
| 230 | | |
| — | |
Shareholders' equity | |
| 128,861 | | |
| 145,627 | |
| |
| | | |
| | |
Total liabilities and shareholders’ equity | |
$ | 132,666 | | |
$ | 149,122 | |
ESSA PHARMA INC.
CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS
(Unaudited)
Amounts in thousands of United States dollars, except
share and per share data
| |
Three months ended June 30, 2024 | |
Three months ended June 30, 2023 | |
Nine months ended June 30, 2024 | |
Nine months ended June 30, 2023 |
| |
| |
| |
| |
|
OPERATING EXPENSES | |
| | | |
| | | |
| | | |
| | |
Research and development | |
$ | 5,484 | | |
$ | 6,271 | | |
$ | 17,039 | | |
$ | 16,096 | |
Financing costs | |
| — | | |
| 2 | | |
| — | | |
| 6 | |
General and administration | |
| 3,154 | | |
| 2,639 | | |
| 9,688 | | |
| 8,889 | |
| |
| | | |
| | | |
| | | |
| | |
Total operating expenses | |
| (8,638 | ) | |
| (8,912 | ) | |
| (26,727 | ) | |
| (24,991 | ) |
| |
| | | |
| | | |
| | | |
| | |
Interest and other items | |
| 1,405 | | |
| 1,613 | | |
| 4,539 | | |
| 3,892 | |
| |
| | | |
| | | |
| | | |
| | |
Net loss before taxes | |
| (7,233 | ) | |
| (7,299 | ) | |
| (22,188 | ) | |
| (21,099 | ) |
Income tax expense (recovery) | |
| — | | |
| — | | |
| — | | |
| (2 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss for the period | |
| (7,233 | ) | |
| (7,299 | ) | |
| (22,188 | ) | |
| (21,101 | ) |
| |
| | | |
| | | |
| | | |
| | |
OTHER COMPREHENSIVE LOSS | |
| | | |
| | | |
| | | |
| | |
Unrealized gain on short-term investments | |
| 1 | | |
| 43 | | |
| 20 | | |
| 13 | |
| |
| | | |
| | | |
| | | |
| | |
Comprehensive loss for the period | |
$ | (7,232 | ) | |
$ | (7,256 | ) | |
$ | (22,168 | ) | |
$ | (21,088 | ) |
| |
| | | |
| | | |
| | | |
| | |
Basic and diluted loss per common share | |
$ | (0.16 | ) | |
$ | (0.17 | ) | |
$ | (0.50 | ) | |
$ | (0.48 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted average number of common shares outstanding | |
| 44,365,505 | | |
| 44,092,374 | | |
| 44,243,638 | | |
| 44,085,941 | |
v3.24.2.u1
Cover
|
Aug. 05, 2024 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 05, 2024
|
Entity File Number |
001-37410
|
Entity Registrant Name |
ESSA Pharma Inc.
|
Entity Central Index Key |
0001633932
|
Entity Tax Identification Number |
98-1250703
|
Entity Incorporation, State or Country Code |
A1
|
Entity Address, Address Line One |
Suite 720
|
Entity Address, Address Line Two |
999 West Broadway
|
Entity Address, City or Town |
Vancouver
|
Entity Address, State or Province |
BC
|
Entity Address, Country |
CA
|
Entity Address, Postal Zip Code |
V5Z 1K5
|
City Area Code |
778
|
Local Phone Number |
331-0962
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common Shares, no par value
|
Trading Symbol |
EPIX
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionISO 3166-1 alpha-2 country code.
+ References
+ Details
Name: |
dei_EntityAddressCountry |
Namespace Prefix: |
dei_ |
Data Type: |
dei:countryCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
ESSA Pharma (NASDAQ:EPIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ESSA Pharma (NASDAQ:EPIX)
Historical Stock Chart
From Sep 2023 to Sep 2024